Hillstream BioPharma, Inc. (NASDAQ:HILS – Get Free Report)’s stock price traded down 5% on Tuesday . The stock traded as low as $0.36 and last traded at $0.39. 409,289 shares traded hands during trading, a decline of 71% from the average session volume of 1,388,685 shares. The stock had previously closed at $0.41.
Hillstream BioPharma Trading Down 5.0 %
The firm has a market cap of $6.86 million, a PE ratio of -0.54 and a beta of 3.08. The stock has a fifty day simple moving average of $0.50 and a two-hundred day simple moving average of $0.33.
Institutional Trading of Hillstream BioPharma
A number of large investors have recently modified their holdings of HILS. Geode Capital Management LLC bought a new stake in Hillstream BioPharma in the 1st quarter worth approximately $30,000. Citadel Advisors LLC bought a new stake in Hillstream BioPharma in the 3rd quarter worth approximately $36,000. Finally, Jane Street Group LLC bought a new stake in Hillstream BioPharma in the 1st quarter worth approximately $38,000. Institutional investors own 13.36% of the company’s stock.
Hillstream BioPharma Company Profile
Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors.
- Five stocks we like better than Hillstream BioPharma
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Is the dip in Atlassian stock a sneaky buy opportunity?
- How to Invest in Energy
- Caterpillar stock hits new highs; time to ring the register?
- Where Do I Find 52-Week Highs and Lows?
- 5 medical stocks growing earnings by triple digits
Receive News & Ratings for Hillstream BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.